Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 18;7(6):e1434468.
doi: 10.1080/2162402X.2018.1434468. eCollection 2018.

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Lisa Derosa  1   2   3   4 , Bertrand Routy  1   2   3   4   5   6 , Guido Kroemer  7   8   9   10   11   12   10   13 , Laurence Zitvogel  1   2   3   4   5   6   7   8   9   10   11   12   10   13   14
Affiliations

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Lisa Derosa et al. Oncoimmunology. .

Abstract

Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

Keywords: Biomarkers; Inflammation and cancer; Microbiota; NSCLC; New target; PD-1/PD-L1; RCC; immune checkpoint blockers.

PubMed Disclaimer

References

    1. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, et al.. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84. doi: 10.1126/science.aad1329. PMID:26541610. - DOI - PMC - PubMed
    1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al.. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13. doi: 10.1056/NEJMoa1510665. PMID:26406148. - DOI - PMC - PubMed
    1. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu T-E, Badin F, et al.. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med. 2017;376:2415–26. doi: 10.1056/NEJMoa1613493. PMID:28636851. - DOI - PMC - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al.. nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–39. doi: 10.1056/NEJMoa1507643. PMID:26412456. - DOI - PMC - PubMed
    1. Le DT Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al.. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. doi: 10.1056/NEJMoa1500596. PMID:26028255. - DOI - PMC - PubMed

Publication types